Oehadian Amaylia, Santoso Prayudi, Menzies Dick, Ruslami Rovina
Division of Hematology and Oncology Medic, Department of Internal Medicine Faculty of Medicine, Universitas Padjadjaran/ Dr. Hasan Sadikin General Hospital, Bandung, Indonesia.
Doctoral Study Program, Faculty of Medicine, Universitas Padjadjaran, Bandung, West Java, Indonesia.
IDCases. 2022 Jul 29;29:e01591. doi: 10.1016/j.idcr.2022.e01591. eCollection 2022.
Linezolid is now recommended as a first line drug for Multidrug Resistant Tuberculosis (MDR-TB). Previous studies reported hematologic toxicity as one of the main side effects. The mechanism of this toxicity is mitochondrial dysfunction, for which a biomarker is Growth differentiation factor-15 (GDF-15). There is no previous report about GDF-15 and its association with hematologic toxicity from Linezolid in the treatment of MDR-TB. We present three cases of MDR-TB involving severe anemia associated with linezolid who had GDF-15 elevation. These cases highlight the need for more research into the relationship between GDF-15 and hematologic toxicity in MDR-TB patients treated with linezolid.
利奈唑胺现已被推荐作为耐多药结核病（MDR-TB）的一线用药。既往研究报道血液学毒性是其主要副作用之一。这种毒性的机制是线粒体功能障碍，生长分化因子-15（GDF-15）是其生物标志物。此前尚无关于GDF-15及其与利奈唑胺治疗MDR-TB时血液学毒性关联的报道。我们报告了3例MDR-TB患者，他们在使用利奈唑胺治疗时出现严重贫血且GDF-15升高。这些病例凸显了有必要进一步研究GDF-15与接受利奈唑胺治疗的MDR-TB患者血液学毒性之间的关系。
